Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6622-6627

  Farazi, Paraskevi A ^a,c   Zeisberg, Michael ^c   Glickman, Jonathan ^b   Zhang, Yan ^a   Kalluri, Raghu ^c,d,e   DePinho, Ronald A ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NITRIC OXIDE SYNTHASE; PROTEIN P53; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT INJURY; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER CIRRHOSIS; MICROENVIRONMENT; MOUSE; MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CADHERINS; CARBON TETRACHLORIDE POISONING; CHOLANGIOCARCINOMA; CYCLOOXYGENASE 2; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; GERM-LINE MUTATION; HYPERPLASIA; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE;

EID: 33746126998     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4609     Document Type: Article

References (48)

1. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002;17:1049-55.
2. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005;41:5-15.
3. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 2002;17:1056-63.
4. Kuper H, Ye W, Broome U et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001;34:714-8.
5. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-7.
6. Polizos A, Kelekis N, Sinani C, Patsiaoura K, Papadamou G, Dalekos GN. Advanced intrahepatic cholangiocarcinoma in hepatitis C virus-related decompensated cirrhosis: case report and review of the literature. Eur J Gastroenterol Hepatol 2003;15:331-4.
7. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620-6.
8. Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004;95:592-5.
9. Nakanuma Y, Yamaguchi K, Ohta G, Terada T. Pathologic features of hepatolithiasis in Japan. Hum Pathol 1988;19:1181-6.
10. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
11. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-90.
12. Shiojiri N, Koike T. Differentiation of biliary epithelial cells from the mouse hepatic endodermal cells cultured in vitro. Tohoku J Exp Med 1997;181:1-8.
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
14. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7:17-23.
15. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
16. Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2001;130:22-8.
17. Kim DG, Park SY, You KR, et al. Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Genes Chromosomes Cancer 2001;30:48-56.
18. Momoi H, Itoh T, Nozaki Y, et al. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol 2001;35:235-44.
19. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999;35:230-40.
20. Tullo A, D'Erchia AM, Honda K, et al. New p53 mutations in hilar cholangiocarcinoma. Eur J Clin Invest 2000;30:798-803.
21. 1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002;33:877-83.
22. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001;91:1332-41.
23. Limpaiboon T, Sripa B, Wongkham S, Bhudhisawasdi V, Chau-in S, Teerajetgul Y. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma. Hepatogastroenterology 2004;51:25-8.
24. Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation, and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002;49:604-8.
25. Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod Pathol 2000;13:1265-8.
26. Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 1998;27:383-91.
27. Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6.
28. Alpini G, Elias I, Glaser SS, et al. γ-Interferon inhibits secretin-induced choleresis and cholangiocyte proliferation in a murine model of cirrhosis. J Hepatol 1997;27:371-80.
29. Blair A, Decoufle P, Grauman D. Causes of death among laundry and dry cleaning workers. Am J Public Health 1979;69:508-11.
30. Hernberg S, Korkala ML, Asikainen U, Riala R. Primary liver cancer and exposure to solvents. Int Arch Occup Environ Health 1984;54:147-53.
31. LeSage GD, Benedetti A, Glaser S, et al. Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. Hepatology 1999;29:307-19.
32. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
33. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65.
34. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-49.
35. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
36. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998;15:259-69.
37. Nakanuma Y, Hoso M, Terada T. Role of progenitor cells in carcinogenesis. In: Bruix J, Berr F, Hauss J, Wands J, Wittekind C, editors. Malignant liver tumours: basic concepts and clinical management. Dordrecht: Kluwer Academic Publishers; 2003. p. 279-90.
38. Branden C, Tooze J. DNA recognition by eucaryotic transcription factors. In: Introduction to protein structure. 2nd ed. New York: Garland Publishing, Inc.; 1999. p. 166-71.
39. Castro GD, Diaz Gomez MI, Castro JA. DNA bases attack by reactive metabolites produced during carbon tetrachloride biotransformation and promotion of liver microsomal lipid peroxidation. Res Commun Mol Pathol Pharmacol 1997;95:253-8.
40. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003;33:105-36.
41. Caulfield JL, Wishnok JS, Tannenbaum SR. Nitric oxide-induced deamination of cytosine and guanine in deoxynucleosides and oligonucleotides. J Biol Chem 1998;273:12689-95.
42. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;36:439-50.
43. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 2004;287:G88-95.
44. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269-78.
45. Goodman JE, Hofseth LJ, Hussain SP, Harris CC. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004;44:3-9.
46. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
47. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
48. Farazi PA, Glickman J, Horner J, DePinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006;66:4766-73.